119 related articles for article (PubMed ID: 9353402)
1. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors.
Van Der Graaf PH; Van Schaick EA; Math-ot RA; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1997 Nov; 283(2):809-16. PubMed ID: 9353402
[TBL] [Abstract][Full Text] [Related]
2. Analysis of drug-receptor interactions in vivo: a new approach in pharmacokinetic-pharmacodynamic modelling.
Van der Graaf PH; Danhof M
Int J Clin Pharmacol Ther; 1997 Oct; 35(10):442-6. PubMed ID: 9352393
[TBL] [Abstract][Full Text] [Related]
3. Mechanism-based pharmacokinetic-pharmacodynamic modeling of antilipolytic effects of adenosine A(1) receptor agonists in rats: prediction of tissue-dependent efficacy in vivo.
Van der Graaf PH; Van Schaick EA; Visser SA; De Greef HJ; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1999 Aug; 290(2):702-9. PubMed ID: 10411581
[TBL] [Abstract][Full Text] [Related]
4. 8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo.
Van Schaick EA; Math-ot RA; Gubbens-Stibbe JM; Langemeijer MW; Roelen HC; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1997 Nov; 283(2):800-8. PubMed ID: 9353401
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic relationship of the cardiovascular effects of adenosine A1 receptor agonist N6-cyclopentyladenosine in the rat.
Mathôt RA; van Schaick EA; Langemeijer MW; Soudijn W; Breimer DD; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1994 Feb; 268(2):616-24. PubMed ID: 8113972
[TBL] [Abstract][Full Text] [Related]
6. Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats.
van Schaick EA; Tukker HE; Roelen HC; IJzerman AP; Danhof M
Br J Pharmacol; 1998 Jun; 124(3):607-18. PubMed ID: 9647488
[TBL] [Abstract][Full Text] [Related]
7. Partial agonism of the nonselective adenosine receptor agonist 8-butylaminoadenosine at the A1 receptor in vivo.
Mathot RA; Wenden EM; Soudijn W; Breimer DD; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1996 Dec; 279(3):1439-46. PubMed ID: 8968369
[TBL] [Abstract][Full Text] [Related]
8. 5'-substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor.
van der Wenden EM; Carnielli M; Roelen HC; Lorenzen A; von Frijtag Drabbe Künzel JK; IJzerman AP
J Med Chem; 1998 Jan; 41(1):102-8. PubMed ID: 9438026
[TBL] [Abstract][Full Text] [Related]
9. N6,C8-distributed adenosine derivatives as partial agonists for adenosine A1 receptors.
Roelen H; Veldman N; Spek AL; von Frijtag Drabbe Künzel J; Mathôt RA; IJzerman AP
J Med Chem; 1996 Mar; 39(7):1463-71. PubMed ID: 8691477
[TBL] [Abstract][Full Text] [Related]
10. Modelling of the pharmacodynamic interaction of an A1 adenosine receptor agonist and antagonist in vivo: N6-cyclopentyladenosine and 8-cyclopentyltheophylline.
Appel S; Mathôt RA; Langemeijer MW; IJzerman AP; Danhof M
Br J Pharmacol; 1995 Aug; 115(7):1253-9. PubMed ID: 7582553
[TBL] [Abstract][Full Text] [Related]
11. Mechanism-based pharmacokinetic-pharmacodynamic modeling of 5-HT1A receptor agonists: estimation of in vivo affinity and intrinsic efficacy on body temperature in rats.
Zuideveld KP; Van der Graaf PH; Newgreen D; Thurlow R; Petty N; Jordan P; Peletier LA; Danhof M
J Pharmacol Exp Ther; 2004 Mar; 308(3):1012-20. PubMed ID: 14718609
[TBL] [Abstract][Full Text] [Related]
12. Deoxyribose analogues of N6-cyclopentyladenosine (CPA): partial agonists at the adenosine A1 receptor in vivo.
Mathôt RA; Van der Wenden EM; Soudijn W; IJzerman AP; Danhof M
Br J Pharmacol; 1995 Oct; 116(3):1957-64. PubMed ID: 8640332
[TBL] [Abstract][Full Text] [Related]
13. Mechanism-based pharmacodynamic modeling of S(-)-atenolol: estimation of in vivo affinity for the beta1-adrenoceptor with an agonist-antagonist interaction model.
van Steeg TJ; Freijer J; Danhof M; de Lange EC
J Pharmacol Exp Ther; 2008 Mar; 324(3):1234-42. PubMed ID: 18162599
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic-pharmacodynamic modelling of the anti-lipolytic and anti-ketotic effects of the adenosine A1-receptor agonist N6-(p-sulphophenyl)adenosine in rats.
van Schaick EA; de Greef HJ; Langemeijer MW; Sheehan MJ; IJzerman AP; Danhof M
Br J Pharmacol; 1997 Oct; 122(3):525-33. PubMed ID: 9351510
[TBL] [Abstract][Full Text] [Related]
15. Adenosine A1 receptor agonist N6-cyclopentyladenosine affects the inactivation of acetylcholinesterase in blood and brain by sarin.
Bueters TJ; Joosen MJ; van Helden HP; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 2003 Mar; 304(3):1307-13. PubMed ID: 12604711
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic modelling of the cardiovascular effects of R- and S-N6-phenylisopropyladenosine in conscious normotensive rats.
Mathôt RA; Van den Aarsen BC; Soudijn W; Breimer DD; Ijzerman AP; Danhof M
J Pharmacol Exp Ther; 1995 Apr; 273(1):405-14. PubMed ID: 7714796
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of a simple behavioral response mediated selectively by central adenosine A1 receptors, using in vivo and in vitro techniques.
Marston HM; Finlayson K; Maemoto T; Olverman HJ; Akahane A; Sharkey J; Butcher SP
J Pharmacol Exp Ther; 1998 Jun; 285(3):1023-30. PubMed ID: 9618404
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular effects of the adenosine A1 receptor agonist N6-cyclopentyladenosine (CPA) decisive for its therapeutic efficacy in sarin poisoning.
Joosen MJ; Bueters TJ; van Helden HP
Arch Toxicol; 2004 Jan; 78(1):34-9. PubMed ID: 14508639
[TBL] [Abstract][Full Text] [Related]
19. Negative chronotropic response to adenosine receptor stimulation in rat right atria after run training.
Priviero F; De Nucci G; Antunes E; Zanesco A
Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):741-3. PubMed ID: 15554918
[TBL] [Abstract][Full Text] [Related]
20. Hydrogen peroxide-induced stimulation of L-type calcium current in guinea pig ventricular myocytes and its inhibition by adenosine A1 receptor activation.
Thomas GP; Sims SM; Cook MA; Karmazyn M
J Pharmacol Exp Ther; 1998 Sep; 286(3):1208-14. PubMed ID: 9732380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
